Endeavor BioMedicines Boosts Leadership with New Board Member Bill Bradford, M.D., Ph.D.

Endeavor BioMedicines, a biotech firm focused on advancing groundbreaking treatments for life-threatening conditions, has named Dr. Williamson "Bill" Bradford, M.D., Ph.D., to its board of directors. With more than 20 years of experience in the industry, Dr. Bradford adds valuable leadership and specialized knowledge in clinical development, particularly in the field of idiopathic pulmonary fibrosis (IPF).

John Hood, Ph.D., Co-Founder, CEO and Chairman, Endeavor, said in a statement, “As we advance the clinical program for ENV-101, our lead investigational candidate in idiopathic pulmonary fibrosis, Dr. Bradford’s extensive knowledge and background in fibrotic lung disease – from the clinic to regulatory approval – will be an invaluable resource to our team. He is widely recognized for his executive and scientific leadership and we are honored to welcome him to our Board of Directors.”

Dr. Bradford boasts over 25 years in the biopharmaceutical sector, excelling in executive leadership, product development, medical affairs, and board roles. As Principal at Teton Bioscience since 2015, he has specialized in drug development and strategic advisory services. He co-founded Indalo Therapeutics, a clinical-stage company focusing on fibrosis, where he served as Board Director and Chief Medical Officer until 2020.

Previously, Dr. Bradford was Senior Vice President of Clinical Development at InterMune, Inc. (now part of Roche). There, he spearheaded the development of Esbriet® (pirfenidone), an FDA-approved treatment for idiopathic pulmonary fibrosis (IPF), and advanced various therapeutics across multiple therapeutic areas. Early in his career, he worked in product development at Genentech (a Roche Group member) and IntraBiotics Pharmaceuticals, and was an infectious disease specialist and researcher at the University of California, San Francisco.

Dr. Bradford, “There is significant need to transform the current standard of care and improve quality of life for patients with idiopathic pulmonary fibrosis, and I believe Endeavor BioMedicines’ ENV-101 has the potential to change the trajectory of this life-threatening disease. I look forward to helping the Endeavor team accelerate the development of ENV-101 to bring this exciting new treatment option to patients suffering from fibrotic lung disease.”